Kornimate/medical-research-clean huggingface dataset:
merging yoga and self-management skills for symptoms of long covid

Conditions: Long COVID

Summary: long covid patients experience high symptom burden for many months after initial infection of the covid-19 virus. this study will investigate a mobile intervention merging yoga and self-management skills (my-skills mobile) as a complementary therapy for fatigue, pain, mood and quality of life in long covid patients at the uchealth center for integrative medicine. the study aim is to assess the feasibility and acceptability of my-skills mobile and research procedures including planned assessments.


Eligibility criteria:
inclusion criteria: * patients referred to the uc health integrated medicine clinic for long covid * community-dwelling * speak english * able to provide informed consent * stand with or without an assistive device * complete the exercise assessment and screening for you (easy) tool; potential participants will receive instructions about safe physical activity and/or to obtain physician approval prior to enrollment. participants will not be excluded due to limited technology access. we will loan tablets and hotspots to participants who do not have hardware or internet. exclusion criteria: * current yoga ≥120 minutes a week * completed self-management education in the last year * cognitive impairment limiting participation in decision making
a trial to study the effect of vitamin d supplementation on glucose and insulin metabolism in centrally obese men

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; Obesity

Summary: the purpose of the study is to evaluate the change in glucose and insulin metabolism(early markers for development of diabetes) after 6 weeks of weekly vitamin d supplementation. as vitamin d has been reported to be associated with lipid levels, crp and blood pressure , we will also be measuring the changes in these variables.

accumulating evidence suggests that serum vitamin d levels may be inversely related to the prevalence of diabetes, to the concentration of glucose , insulin resistance and metabolic syndrome.these results have been replicated in patients at risk for diabetes with documentation of impairment in insulin secretion in vitamin d deficient subjects. therefore, vitamin d could be implicated in the pathogenesis of type 2 diabetes, by affecting either insulin sensitivity or ß cell function, or both. however, there is paucity of literature on the effect of vitamin d supplementation on insulin resistance or glucose metabolism. as vitamin d has been reported to be associated with lipid levels, crp and blood pressure , we will also be measuring the changes in these variables.

Eligibility criteria:
inclusion criteria: * male * ≥35 years of age * waist circumference ≥78 cm exclusion criteria: * diabetic- fasting blood sugar \>126 mg/dl or on anti-diabetic medication * bp\>140/90 or on anti-hypertensive medication * receiving vitamin d or calcium supplementation * chronic disease-renal/hepatic/malignancy/gastrointestinal * on any medication within the last one month which could potentially influence insulin secretion, insulin sensitivity, vitamin d or calcium metabolism * febrile illness or infective morbidity in the past 10 days * past history of nephrolithiasis

Keywords: vitamin d diabetes insulin sensitivity obesity
study for the treatment of crohn's disease with adacolumn

Conditions: Crohn's Disease

Summary: the purpose of this study is to evaluate the safety and effectiveness of the adacolumn apheresis system as a treatment for the signs and symptoms of crohn's disease.

trial features: * medical device (non-drug option) * most patients can remain on current treatment regimen throughout the study components of the study: * study length is 24 weeks, which includes a screening visit, ten treatment visits over nine weeks and 4 follow-up appointments * physical exams, laboratory tests and disease assessments conducted at no charge to the patient * 2:1 randomization (treatment:sham) * open-label extension offered to eligible patients

Eligibility criteria:
key inclusion criteria: * moderate to severe crohn's disease * adequate peripheral venous access * agree to participate in the required follow-up visits * able to complete a diary * signed written informed consent document and authorization for use of protected health information key exclusion criteria: * extremely severe crohn's disease * known obstructive symptoms within the past 3 months * presence of toxic megacolon * major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks * total colectomy, ileostomy, stoma or 100 cm of resected small bowel * requiring in-patient hospitalization * a history of allergic reaction to heparin or heparin-induced thrombocytopenia * a history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures * a history of severe cardiovascular or peripheral arterial diseases * a history of cerebral vascular diseases * liver diseases * renal insufficiency * known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment * any hypercoagulable disorder * known infection with hepatitis b or c, or hiv * severe anemia * leukopenia or granulocytopenia * evidence of current systemic infection * malignancy * pregnant, lactating or planning to become pregnant during the course of the investigational study * used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic

Keywords: crohn's disease
figure-of-eight walk test in parkinson

Conditions: Parkinson Disease

Summary: the aim of study is to assess validity and reliability of figure-of-eight walk test in people with parkinson's disease


Eligibility criteria:
inclusion criteria: * at least 40 years of age * neurologist-diagnosed parkinson's disease * hoehn \& yahr (h\&y) stages 1 to 3 * able to walk at least 20 meters exclusion criteria: * other neurologic disorder * visual, auditory, orientational problems that could affect study results * any orthopedic problem that prevents walking and standing * have a cardiovascular, pulmonary or hormonal disorder
a study of tislelizumab (bgb-a317) in combination with chemotherapy as first line treatment in participants with advanced esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Summary: the purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (escc).


Eligibility criteria:
key inclusion criteria: 1. pathologically (histologically) confirmed diagnosis of escc 2. stage iv unresectable escc at first diagnosis or unresectable, locally advanced recurrent or metastatic disease (per american joint committee on cancer 7th edition), if there is prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy, a treatment-free interval of at least 6 months is required. key exclusion criteria: 1. palliative radiation treatment for escc within 4 weeks of study treatment initiation 2. prior systemic therapy for unresectable, locally advanced recurrent or metastatic escc 3. received prior therapies targeting programmed cell death protein-1 (pd-1), programmed cell death protein ligand-1 (pd-l1) or pd-l2 4. participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta) 5. uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (clinically significant recurrence requiring an additional intervention within 2 weeks of intervention) 6. evidence of complete esophageal obstruction not amenable to treatment 7. unintentional weight loss ≥ 5% within one month prior to randomization or nutritional risk index (nri) \< 83.5 per investigator's choice 8. locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator. 9. participants with untreated chronic hepatitis b or chronic hepatitis b virus (hbv) carriers whose hbv dna is ≥ 500 iu/ml or participants with active hepatitis c virus (hcv) note: other protocol defined inclusion/exclusion criteria may apply.
stereotactic body radiotherapy vs conventional palliative radiotherapy for painful non-spine bone metastases

Conditions: Cancer Metastatic

Summary: this study is being done to answer the following question: is stereotactic body radiation therapy or sbrt (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or crt (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)

this is a multi-centre, phase iii randomized controlled trial comparing sbrt to conventional palliative ebrt in patients with solid tumours and a dominant painful non-spine bone metastasis as defined by a worst pain score of 2 or greater. 230 participants will be enrolled to the study. participants will have radiation for 5 treatments (conventional palliative ebrt 20gy/5; sbrt 30gy/5 or 35gy/5) and then will be followed for pain response and radiological progression at 3 and 6 months post treatment.

Eligibility criteria:
inclusion criteria: * histologic confirmation of solid tumour. * patient with a dominant painful non-spine bone metastasis and a worst minimum pain score of 2 using the bpi attributed to that dominant site * expected overall survival of greater than 6 months as determined by the treating physician * suitable for protocol defined sbrt and crt. * stable pain with no immediate plan to alter analgesic regimen. * ecog performance status of 0-2. * participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate exclusion criteria: * metastases of the hands, feet, cranium and spine (including sacrum). * bone metastasis arising from a small cell or germ cell. * radionuclide therapy within 30 days of randomization. * patient treated with prior palliative rt to the dominant painful bone metastasis site (prior radiation exposure is permitted if prior to development of the dominant metastasis and would not influence the applicability of either treatment arm of the current study). * received systemic chemotherapy within 1 week of the protocol rt, or who are expected/planned to receive chemotherapy within one week of completing protocol rt. * participants with an unstable pathologic fracture at the dominant painful bone metastasis, or for whom surgical fixation would be the preferred intervention if possible. * pregnant or lactating individuals.
dermal phototoxicity study

Conditions: Healthy

Summary: dermal safety study to determine the phototoxicity potential of fmx-101 4% in healthy volunteers


Eligibility criteria:
inclusion criteria: 1. healthy male or female volunteers age 18 years or older 2. has uniformly-colored skin on the lower thoracic area of the back which allowed discernment of erythema, and were fitzpatrick skin types i, ii, or iii exclusion criteria: 1. has any visible disease at the application site which, in the opinion of the investigative personnel, would have interfered with the evaluation of the test site reaction 2. are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study
liraglutide use in prader-willi syndrome

Conditions: Diabetes Mellitus Type 2; Prader Willi Syndrome

Summary: liraglutide is a glucagon like peptide -1 (glp-1) agonist, which is approved for use in patients with type 2 diabetes. studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. liraglutide use in the treatment of pws is limited to one case report by cyganek et el (see attached citation). in this case report, the subject showed improvements in hemoglobin a1c and body weight over 14 weeks. the investigators plan to examine the use of liraglutide in a single subject with prader willi syndrome and type 2 diabetes for one year. the investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.


Eligibility criteria:
inclusion criteria: * prader willi syndrome, diabetes type 2 exclusion criteria: * previous or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia syndrome. * subjects with acute or chronic pancreatitis

Keywords: diabetes mellitus type 2 prader willi syndrome
a research study to determine the safety and efficacy of glucovance compared to metformin and glyburide in children and adolescents with type 2 diabetes.

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Summary: the purpose of this clinical research study is to see if glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age.


Eligibility criteria:
children ages 9-16 years with a diagnosis of type 2 diabetes mellitus who are not adequately controlled with diet and exercise, with or without oral hypoglycemic therapy, and have an hba1c greater than 6.4%

Keywords: diabetes mellitus, type ii
the added value of bone microstructure assessment in the management of osteoporotic bone

Conditions: Osteoporosis

Summary: 1. to assess the clinical utility of trabecular bone score (tbs) on fracture risk prediction including the new version (tbs v4) and future tbs versions at the spine and hip. 2. to assess the clinical utility of tbs software as a potential treatment outcome: sensitivity to change over time and following osteoporosis therapy. 3. to compare tbs to other imaging modalities of bone structure such as quantitative computed tomography (qct) in fracture risk prediction and response to osteoporosis therapy.


Eligibility criteria:
inclusion criteria: has had a dexa scan * has had a dexa scan exclusion criteria: * unable to complete dexa scan
the influence of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on renal function in patients undergoing non-emergent coronary angiography

Conditions: Blood Pressure

Summary: the aim of the current study is to evaluate prospectively whether concomitant administration of raas blockers (namely ace-i and arbs') influence the change in estimated gfr (egfr) after administration of contrast media in patients undergoing non-emergent coronary angiography.


Eligibility criteria:
inclusion criteria: * 1. age\>18 years * 2. subjects on chronic therapy with ace-i and/or arbs' (confirmed by electronic records in their medical file) * 3. subjects planned to undergo non-emergent coronary angiography. * 4. signed informed consent exclusion criteria: * 1. egfr\<30 ml/min at baseline * 2. chronic utilization of nsaids and cox-2 selective inhibitors * 3. chronic treatment with mineralocorticosteroid receptor blocker * 4. systolic blood pressure\<90 mmhg * 5. planned staged (repeated) procedure within 48 hours * 6. administration of contrast within 14 days prior to the enrollment * 7. contraindication to stop ace-i or arb's

Keywords: change in egfr from baseline to 72 hours following the exposure to the contrast. rate of egfr decrease>25% from the baseline length of hospitalization. requirement of unplanned therapy for elevated blood pressure
gnrh antagonist to prepare recipients for embryo transfer

Conditions: Infertility

Summary: 26% of all art cycles performed in the usa in 2003 (cdc data) are frozen embryo transfers (fet) and transfer of embryos resulting from egg donation (ed) to recipients. the typical protocol used to prepare a recipient for et involves gnrh agonist (lupron, tap pharmaceuticals) to down regulate the patient. a gnrh antagonist, such as cetrotide (emd serono), is comparable to gnrh agonist and fda approved to prevent spontaneous ovulation with art treatment, and its usage decreases significantly the number of injections that the patient receives with treatment. the working hypothesis for this study is that the gnrh antagonist (cetrotide) can be used instead of an agonist to achieve effective down regulation in fet and ed cycles. presumably, patients will prefer cetrotide over lupron because of the markedly fewer injections required.


Eligibility criteria:
inclusion criteria: * history of infertility before cryopreserving the embryos or inability to conceive from her own oocytes (based on age and/or a serum fsh \> 15 iu/l). * any patient desiring to become pregnant as a result of transferring frozen-thawed embryos generated using her own or donor oocytes. * subject is in good health as determined by the investigator on the basis of medical history, physical examination and laboratory screening tests. * a negative pregnancy test prior to starting treatment with estrogens. exclusion criteria: * women with a history of liver and/or kidney disease * hypertension: systolic pressure over 180 mm hg or diastolic pressure over 105 at any study visit, measured twice 6 hours apart despite active treatment for hypertension. * liver function tests of two times than the upper limit of normal * women with active sever endometriosis.

Keywords: frozen embryo transfers (fet). egg donation (ed). ivf. art. implantation. gnrh antagonist. cetrotide. endometrial response. infertility treatments: transfer of embryos from egg donation (ed) to recipients.
tachycardia as an indication for prophylactic phenylephrine injection in caesarean section under spinal anesthesia; an observational study

Conditions: Anesthesia

Summary: the value of phenylephrine administration in response to tachycardia in preventing hypotension after spinal anesthesia in elective cesarean section.

this observational study will take place at ain shams university maternity hospitals, cairo, egypt. all patients will sign written informed consent before inclusion. sample size: using pass 15 program for sample size calculation, setting confidence level at 95% and margin of error at 0.05, it is estimated that sample size of 80 women will be needed to detect an expected incidence rate of hypotension after phenylephrine administration of 30% "hasanin et al., 2019" inclusion criteria: asa ii pregnant female planned for elective c.s., aged between 18 -35 years old. exclusion criteria: emergency cs, complicated cs (severe bleeding, organ injury, uterine atony), asa iii, vi \& patients with cardiovascular diseases for all pregnant females including whose in the study group, preoperative labs will be done including ( cbc, inr, liver function \& kidney function) , oral and written informed consents will be taken from the patients with explanation of the spinal anesthesia and expected complications. in or wide pore iv access and preload started with crystalloids, full standard monitoring, spinal anesthesia will be performed by the expert anesthetist. the pregnant female will be in the sitting position and complete sterilization of her back, local anesthesia by 5 ml lidocaine 1% then the spinal needle (pencil point 27 g) introduced between l4-5 and injection of (50 µg fentanyl + bupivacaine 0.5%) in total volume between 1.8 - 2.3 according to patient's height. then patient will lie supine with head elevated 30 degrees by a bellow and start recording the data just after spinal anesthesia. phenylephrine will be given in a dose of 50 µg iv immediately if the heart rate increases ≥ 20 % of baseline. then blood pressure \& hr will be recorded after the administration of phenylephrine and every 5 minutes. any further doses given will be recorded.

Eligibility criteria:
inclusion criteria: * asa ii pregnant female planned for elective c.s., aged between 18 -35 years old. exclusion criteria: * emergency cs, complicated cs (severe bleeding, organ injury, uterine atony), asa iii, vi patients with cardiovascular diseases

Keywords: caesarean section , hypotension, spinal anesthesia, phenylephrine
correlation between skin carotenoid levels and previous history of skin cancer

Conditions: Skin Cancer; Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: the purpose of this study is to determine the difference of skin carotenoid levels between subjects with previous squamous cell carcinomas (scc), subjects with previous basal cell carcinomas (bcc) and a control group.

there has been experimental and clinical research evaluating association of different carotenoids and incidence of malignancies, including non- melanoma skin cancer (nmsc). an easy and inexpensive way to determine which subjects would benefit from supplementation with carotenoids or retinoids could be the measurement of skin carotenoid levels.the least invasive way to perform it is through raman spectroscopy which is a technique that uses a laser light that can be used to quantify carotenoids on the skin. we will compare the skin carotenoid levels of subjects with previous history of scc or bcc and subjects without history of previous nmsc.

Eligibility criteria:
inclusion criteria: * subjects between 50 and 75 years old without history of previous scc or bcc. * fitzpatrick skin types i-iv. * willing and able to understand and sign informed consent. * able to complete study and comply with study procedures exclusion criteria: * regular ingestion of supplements containing carotenoids or vitamin a in the past 4 weeks. * use of topical retinoids in the past 4 weeks. * treatment with systemic retinoids in the past 6 months. * dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, palmar psoriasis, hand dermatitis or palmo-plantar keratoderma. * previous history of psoriasis. * clinically significant abnormal findings or conditions, which might, in the opinion of the principal investigator, interfere with study evaluations or pose a risk to subject safety during the study. * subjects who are known to be pregnant or planning a pregnancy.

Keywords: non-melanoma skin cancer basal cell carcinoma squamous cell carcinoma
dexamethasone for espb in total hip arthroplasty

Conditions: Hip Osteoarthritis; Hip Arthropathy; Hip Arthritis

Summary: effect of adding dexamethasone to erector spinae plane block in patients undergoing total hip arthroplasty

hip arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. patients may complain of severe pain due to surgical trauma and prostheses. regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Eligibility criteria:
inclusion criteria: * patients scheduled for total hip arthroplasty * patients aged \>65 and \<100 years * patients able to provide informed consent * patients able to reliably report symptoms to the research team exclusion criteria: * inability to provide first-party consent due to cognitive impairment or a language barrier

Keywords: erector spinae plane block total hip arthroplasty pain management perineural adjuvant